secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001193125-23-274580
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV reports positive 2-year OLE results for Viaskin Peanut in toddlers; 81.3% reach 1,000 mg eliciting dose
--------------------------------------------------------------------------------

- After 24 months, 81.3% of subjects reached eliciting dose >=1,000 mg peanut protein vs 64.2% at 12 months.
- 55.9% completed the 3,444 mg DBPCFC without meeting stopping criteria, up from 30.7% at 12 months.
- No treatment-related anaphylaxis or serious TEAEs in second year; local application site reactions decreased.
- Placebo crossover group (12 months VP250) showed 62.7% reaching >=1,000 mg ED; single anaphylaxis event.
- Results to be presented at ACAAI Nov 11; investor call/webcast Nov 9 at 5pm ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312523274580/0001193125-23-274580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312523274580/d286743d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-274580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer